HOME >> BIOLOGY >> NEWS
NIST chemists define and refine properties of plastic microsystems

There may well be a plastic biochip in your future, thanks in part to the National Institute of Standards and Technology (NIST).

Microfluidics devices, also known as "lab-on-a-chip" systems, are miniaturized chemical and biochemical analyzers that one day may be used for quick, inexpensive tests in physicians' offices. Most microfluidics devices today are made of glass materials. Cheaper, disposable devices could be made of plastics, but their properties are not yet well understood.

NIST is contributing to the development of these plastic microfluidics. One study looked at how fluids flowed in plastic microchannels by tracking fluorescent dye in the fluids. NIST researchers also developed an easy technique for accurately measuring fluid temperatures--an important parameter for chemical reactions.

A third project spawned a method for concentrating and separating an ionic (charged) substance in solution within microchannels. The technique concentrates the substance as much as 10,000-fold or more, making it easier to detect in ultrasmall quantities (nanoliters--a billionth of a liter--or less).

Finally, NIST staff designed a novel system to overcome the difficult problem of slow mixing in microfluidics devices. The mixer consists of a T-shaped microchannel imprinted in plastic that is modified with a laser to create a series of slanted wells. The wells speed the mixing of two streams entering the passage.


'"/>

Contact: Michael E. Newman
michael.newman@nist.gov
301-975-3025
National Institute of Standards and Technology (NIST)
26-Aug-2002


Page: 1

Related biology news :

1. NIH roadmap for biomedical research focus of chemists at American Chemical Society meeting
2. New multidisciplinary research tops chemists meeting Aug. 22-26
3. Wisconsin chemists find a new chink in TBs armor
4. UCLA chemists develop new coating for nanoscale probes
5. NJIT chemists pave way for cheap, usable field test for polluted, toxic, water, air, food
6. Frog skin and supercomputers lead Penn chemists to designing better bacteria killers
7. Purdue chemists put the twist on protein building block
8. New pollutant cleanup technique puzzles, pleases chemists
9. Homeland security symposium covers what chemists can do to help protect the nation
10. Michigan, Connecticut and Illinois chemists receive award for drug to combat antibiotic resistance
11. Carnegie Mellon University chemists create versatile polymer brushes

Post Your Comments:
(Date:8/5/2015)... Transparency Market Research has released ... Global Industry Analysis, Size, Share, Growth, Trends and Forecast ... is forecast to reach US$ 2,671.8 Mn by 2022. ... systems by civil and government agencies. This is majorly ... activities across the globe that would elevate the demand ...
(Date:8/3/2015)... JOSE, Calif. , Aug. 3, 2015 ... of human interface solutions, today announced that members of ... community at the Pacific Crest Global Technology Leadership Forum ... Time. The conference will be held at the Sonnenalp ... The presentation may include forward-looking information. An ...
(Date:7/31/2015)... SHENZHEN , Chine, 31 juillet 2015 /PRNewswire/ ... (ICG-10, www.icg-10.org ) sera organisée par le ... Shenzhen en Chine. ... année. Depuis son inauguration en 2006, l,ICG est ... influentes dans le domaine des « omiques » et c,est ...
Breaking Biology News(10 mins):Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3
(Date:8/31/2015)... ... August 31, 2015 , ... Regulatory agencies have ... drug development approval process. Thus, innovator companies must understand what will be needed ... Chicago-based CMO, has been hosting multiple educational panels and seminars for experts to ...
(Date:8/28/2015)... Aug. 28, 2015 Research ... of the "Global & USA BioSimilar Market Analysis ... The highly awaited US Biosimilar market will be initiated ... biologic, Zarxio. How will the global market react? Will ... that biosimilars could save the US economy up to ...
(Date:8/28/2015)... Texas (PRWEB) , ... August 28, 2015 , ... ... Riordan, PhD and orthopedic surgeon, Wade McKenna, DO, announced today that the use ... Dallas, Texas, resulted in complete healing of an otherwise non-healing surgical knee wound. ...
(Date:8/27/2015)... /PRNewswire/ - Portage Biotech Inc. ("Portage") (OTC Market: ... Holding Company Limited (Biohaven), announced today that dosing ... BHV-0223, a glutamate modulating agent. Biohaven filed an ... obtained clearance from the U.S. Food and Drug ... holds 54% equity interest in Biohaven, a private ...
Breaking Biology Technology:Regis Shares Expert Advice on Impurities in Drug Development 2Regis Shares Expert Advice on Impurities in Drug Development 3Global & USA BioSimilar Market Analysis Report 2015-2021 2Global & USA BioSimilar Market Analysis Report 2015-2021 3Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 2Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 3Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 4Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4
Cached News: